Second-line drug susceptibilities of multidrug-resistant Mycobacterium tuberculosis isolates in Aegean Region - Turkey

Simple item page
dc.contributor.authorÖzkütük N.
dc.contributor.authorSürücüoǧlu S.
dc.contributor.authorGazi H.
dc.contributor.authorCoşkun M.
dc.contributor.authorÖzkütük A.
dc.contributor.authorÖzbakkaloǧlu B.
dc.date.accessioned2024-07-22T08:22:15Z
dc.date.available2024-07-22T08:22:15Z
dc.date.issued2008
dc.description.abstractAim: The emergence of multidrug-resistant tuberculosis (MDR-TB) is increasing, and the standard shortcourse regimen used for the treatment of TB is likely to be ineffective against MDR-TB, leading to the need for second-line drugs. In such situations, drug susceptibility testing is necessary to select an appropriate treatment regimen. Unfortunately, there are few studies showing the pattern of the second-line drug resistance in Turkey. We aimed to analyze the resistance to second-line anti-tuberculosis drugs of MDR strains of Mycobacterium tuberculosis isolated from the Aegean region of Turkey. Materials and Methods: In this study, drug susceptibility testing of 40 MDR-TB strains isolated from the Aegean region of Turkey was performed using the BACTEC 460 TB radiometric system. Capreomycin, ethionamide, kanamycin, amikacin, clofazimine and ofloxacin were tested in 1.25 μg/ml, 1.25 μg/ml, 5.0 μg/ml, 1.0 μg/ml, 0.5 μg/ml, and 2.0 μg/ml concentrations, respectively. Results: The results showed that 37.5% of the strains were resistant to ethionamide, 25% to capreomycin, 5% to kanamycin, amikacin and ofloxacin, and 2.5% to clofazimine. One (2.5%) of the 40 MDR-TB cases was defined as extensively drug-resistant tuberculosis (XDR-TB). Conclusions: The results of the study indicate that the high rates of resistance to ethionamide and capreomycin may be a problem in the treatment of patients with MDR-TB; XDR-TB is not yet a serious problem in our region. © TÜBİTAK.
dc.identifier.issn13000144
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/18988
dc.language.isoEnglish
dc.subjectChemotherapy
dc.subjectComputer networks
dc.subjectDrug delivery
dc.subjectDrug dosage
dc.subjectDrug therapy
dc.subjectHealth
dc.subjectMaterials testing
dc.subjectPigments
dc.subjectRadiometry
dc.subjectStandards
dc.subjectamikacin
dc.subjectcapreomycin
dc.subjectclofazimine
dc.subjectethionamide
dc.subjectkanamycin
dc.subjectofloxacin
dc.subjectarticle
dc.subjectbacterium isolation
dc.subjectconcentration (parameters)
dc.subjectdrug sensitivity
dc.subjecthuman
dc.subjectmultidrug resistance
dc.subjectMycobacterium tuberculosis
dc.subjectradiometry
dc.subjecttuberculosis
dc.subjectTurkey (republic)
dc.subjectdrug resistance
dc.subjectDrug susceptibility
dc.subjecthigh rates
dc.subjectKanamycin (KM)
dc.subjectMultidrug resistant tuberculosis
dc.subjectMycobacterium tuberculosis (MtAhpC)
dc.subjectOfloxacin
dc.subjectRadiometric system (RS)
dc.subjectTuberculosis (TB)
dc.subjectTerbium alloys
dc.titleSecond-line drug susceptibilities of multidrug-resistant Mycobacterium tuberculosis isolates in Aegean Region - Turkey
dc.typeArticle

Files

Collections

Scopus Koleksiyonu